Richard A. Larson to Doxorubicin
This is a "connection" page, showing publications Richard A. Larson has written about Doxorubicin.
Connection Strength
0.248
-
Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol. 2015 Nov; 171(3):373-7.
Score: 0.124
-
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995 Apr 15; 85(8):2025-37.
Score: 0.030
-
Circulating immune complexes correlate with remission duration in acute myeloid leukemia. Leukemia. 1991 Feb; 5(2):131-7.
Score: 0.023
-
Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. Am J Med. 1988 Feb; 84(2):233-9.
Score: 0.018
-
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006 Feb 15; 106(4):830-8.
Score: 0.016
-
New high-performance liquid chromatographic assay for plasma doxorubicin. J Chromatogr. 1985 Jan 11; 337(1):194-200.
Score: 0.015
-
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. Blood. 1996 Sep 15; 88(6):2354-5.
Score: 0.008
-
Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. Leukemia. 1990 Feb; 4(2):127-31.
Score: 0.005
-
Low O6-alkylguanine DNA alkyltransferase activity in the peripheral blood lymphocytes of patients with therapy-related acute nonlymphocytic leukemia. Cancer Res. 1988 Jun 01; 48(11):3084-9.
Score: 0.005
-
Nonrandom chromosome abnormalities in angioimmunoblastic lymphadenopathy. Blood. 1982 Oct; 60(4):877-87.
Score: 0.003